

Please see the coverage summary for January 2025 new drug codes below:

Not covered under medical benefit; Redirect to pharmacy for MGB ACO:

J0601	Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
J0602	Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis)
J0603	Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
J0605	Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)
J0607	Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)
J0608	Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)
J0609	Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)
J0615	Calcium acetate, oral, 23 mg (for esrd on dialysis)
J7514	Mycophenolate mofetil (myhibbin), oral suspension, 100 mg
J7601	Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
Q0155	Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q5140	Injection, adalimumab-fkjp, biosimilar, 1 mg
Q5141	Injection, adalimumab-aaty, biosimilar, 1 mg
Q5142	Injection, adalimumab-ryvk biosimilar, 1 mg
Q5143	Injection, adalimumab-adbm, biosimilar, 1 mg
Q5144	Injection, adalimumab-aacf (idacio), biosimilar, 1 mg
Q5145	Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg
Q9996	Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg

Q9998	Injection, ustekinumab-aekn (selarsdi), 1 mg
-------	--

Not covered under medical benefit; Redirect to pharmacy for Commercial:

J0139	Injection, adalimumab, 1 mg
J0601	Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
J0602	Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis)
J0603	Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
J0605	Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)
J0607	Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)
J0608	Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)
J0609	Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)
J0615	Calcium acetate, oral, 23 mg (for esrd on dialysis)
J0901	Vadadustat, oral, 1 mg (for esrd on dialysis)
J7514	Mycophenolate mofetil (myhibbin), oral suspension, 100 mg
J7601	Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
Q0155	Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q5140	Injection, adalimumab-fkjp, biosimilar, 1 mg
Q5141	Injection, adalimumab-aaty, biosimilar, 1 mg
Q5142	Injection, adalimumab-ryvk biosimilar, 1 mg
Q5143	Injection, adalimumab-adbm, biosimilar, 1 mg
Q5144	Injection, adalimumab-aacf (idacio), biosimilar, 1 mg

Q5145	Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg
-------	---

Not covered under medical benefit, Redirect to Pharmacy for Medicare Advantage:

J0139	Injection, adalimumab, 1 mg
Q5140	Injection, adalimumab-fkjp, biosimilar, 1 mg
Q5141	Injection, adalimumab-aaty, biosimilar, 1 mg
Q5142	Injection, adalimumab-ryvk biosimilar, 1 mg
Q5143	Injection, adalimumab-adbm, biosimilar, 1 mg
Q5144	Injection, adalimumab-aacf (idacio), biosimilar, 1 mg
Q5145	Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg

New to Market not covered unless prior authorized for Commercial:

C9173	Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
J9292	Injection, pemetrexed (avyxa), not therapeutically equivalent to j9305, 10 mg
Q5139	Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
Q5146	Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg
Q9996	Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg
Q9997	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
Q9998	Injection, ustekinumab-aekn (selarsdi), 1 mg

New to Market not covered unless prior authorized for MGB ACO:

C9173	Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
J0901	Vadadustat, oral, 1 mg (for esrd on dialysis)

Q5139	Injection, eculizumab-aeab (bkemv), biosimilar, 10 mg
Q9997	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg

New to Market not covered unless prior authorized for Medicare Advantage:

Q5139	Injection, eculizumab-aeab (bkemv), biosimilar, 10 mg
Q5146	Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg
Q9996	Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg
Q9997	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
Q9998	Injection, ustekinumab-aekn (selarsdi), 1 mg

Prior authorization required for Commercial:

J0870	Injection, imetelstat, 1 mg
J1307	Injection, crovalimab-akkz, 10 mg
J1414	Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
J1552	Injection, immune globulin (alyglo), 500 mg
J2802	Injection, romiplostim, 1 microgram
J3392	Injection, exagamglogene autotemcel, per treatment
J9026	Injection, tarlatamab-dlle, 1 mg
J9028	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram

Prior authorization required for MGB ACO:

J0870	Injection, imetelstat, 1 mg
J1307	Injection, crovalimab-akkz, 10 mg

J1414	Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
J1552	Injection, immune globulin (alyglo), 500 mg
J2802	Injection, romiplostim, 1 microgram
J3392	Injection, exagamglogene autotemcel, per treatment
J9026	Injection, tarlatamab-dlle, 1 mg
J9028	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
J9292	Injection, pemetrexed (avyxa), not therapeutically equivalent to j9305, 10 mg
Q5146	Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg

Prior authorization required for Medicare Advantage:

C9173	Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
J0870	Injection, imetelstat, 1 mg
J1307	Injection, crovalimab-akkz, 10 mg
J1414	Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
J3392	Injection, exagamglogene autotemcel, per treatment
J9026	Injection, tarlatamab-dlle, 1 mg
J9028	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
J9292	Injection, pemetrexed (avyxa), not therapeutically equivalent to j9305, 10 mg

No prior authorization required for Commercial:

J0666	Injection, bupivacaine liposome, 1 mg
J2290	Injection, nafcillin sodium, 20 mg

J2472	Injection, pantoprazole sodium in sodium chloride (baxter), 40 mg
J9076	Injection, cyclophosphamide (baxter), 5 mg

No prior authorization required for MGB ACO:

J0139	Injection, adalimumab, 1 mg
J0666	Injection, bupivacaine liposome, 1 mg
J2290	Injection, nafcillin sodium, 20 mg
J2472	Injection, pantoprazole sodium in sodium chloride (baxter), 40 mg
J9076	Injection, cyclophosphamide (baxter), 5 mg

No prior authorization required for Medicare Advantage:

J0601	Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
J0602	Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis)
J0603	Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
J0605	Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)
J0607	Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)
J0608	Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)
J0609	Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)
J0615	Calcium acetate, oral, 23 mg (for esrd on dialysis)
J0666	Injection, bupivacaine liposome, 1 mg
J0901	Vadadustat, oral, 1 mg (for esrd on dialysis)
J1552	Injection, immune globulin (alyglo), 500 mg

J2290	Injection, nafcillin sodium, 20 mg
J2802	Injection, romiplostim, 1 microgram
J7514	Mycophenolate mofetil (myhibbin), oral suspension, 100 mg
J7601	Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
J9076	Injection, cyclophosphamide (baxter), 5 mg
Q0155	Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen